MELA Sciences (MELA) Enters Extended MelaFind Manufacturing Contract with Askion GmbH
Tweet
Share
E-mailGet Alerts MELA Hot Sheet
Join SI Premium – FREE
MELA Sciences, Inc. (Nasdaq: MELA) announced that it has entered into an expanded three-year manufacturing agreement with its long-term supplier, Askion GmbH, for the production of the MelaFind handheld device.
MelaFind is the Company's breakthrough non-invasive and objective automated point of care system for use when a dermatologist chooses to obtain additional information for a decision to biopsy clinically atypical pigmented skin lesions with one or more clinical or historical characteristics of melanoma.
The Company is preparing for commercial launch in the U.S. and the European Union, initially in Germany, which remains on track for the first quarter of 2012.
MelaFind is the Company's breakthrough non-invasive and objective automated point of care system for use when a dermatologist chooses to obtain additional information for a decision to biopsy clinically atypical pigmented skin lesions with one or more clinical or historical characteristics of melanoma.
The Company is preparing for commercial launch in the U.S. and the European Union, initially in Germany, which remains on track for the first quarter of 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Real and RE/MAX Holdings receive court approval for merger
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
